Domains of the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) at enrolment by treatment
| Tocilizumab n=55 | Placebo n=55 | ||
| Skin | 0 | 48 (87.3%) | 48 (88.9%) |
| 1 | 3 (5.5%) | 3 (5.6%) | |
| 2 | 4 (7.3%) | 1 (1.9%) | |
| 3 | 0 (0%) | 2 (3.7%) | |
| Pulmonary | 0 | 44 (80%) | 33 (61.1%) |
| 1 | 8 (14.6%) | 12 (22.2%) | |
| 2 | 2 (3.6%) | 9 (16.7%) | |
| 3 | 1 (1.8%) | 0 (0%) | |
| Renal | 0 | 54 (98.2%) | 54 (100%) |
| 1 | 0 (0%) | 0 (0%) | |
| 2 | 1 (1.8%) | 0 (0%) | |
| 3 | 0 (0%) | 0 (0%) | |
| Articular | 0 | 16 (29.1%) | 13 (24.1%) |
| 1 | 15 (27.3%) | 19 (35.2%) | |
| 2 | 16 (29.1%) | 13 (24.1%) | |
| 3 | 8 (14.6%) | 9 (16.7%) | |
| Muscular | 0 | 51 (92.7%) | 52 (96.3%) |
| 1 | 2 (3.6%) | 1 (1.9%) | |
| 2 | 1 (1.8%) | 1 (1.9%) | |
| 3 | 1 (1.8%) | 0 (0%) | |
| Peripheral neuropathy | 0 | 46 (83.6%) | 45 (83.3%) |
| 1 | 7 (12.7%) | 2 (3.7%) | |
| 2 | 2 (3.6%) | 7 (13.0%) | |
| 3 | 0 (0%) | 0 (0%) | |
| Central nervous system | 0 | 54 (98.2%) | 54 (100%) |
| 2 | 1 (1.8%) | 0 (0%) | |
| 3 | 0 (0%) | 0 (0%) | |
| Glandular | 0 | 26 (47.3%) | 26 (48.2%) |
| 1 | 19 (34.6%) | 16 (29.6%) | |
| 2 | 10 (18.2%) | 12 (22.2%) | |
| Constitutional | 0 | 40 (72.7%) | 39 (72.2%) |
| 1 | 15 (27.3%) | 14 (25.9%) | |
| 2 | 0 (0%) | 1 (1.9%) | |
| Haematological | 0 | 33 (60%) | 30 (55.6%) |
| 1 | 20 (36.4%) | 21 (38.9%) | |
| 2 | 2 (3.6%) | 3 (5.6%) | |
| 3 | 0 (0%) | 0 (0%) | |
| Lymphadenopathy | 0 | 47 (87.0%) | 50 (92.6%) |
| 1 | 6 (11.1%) | 4 (7.41%) | |
| 2 | 1 (1.9%) | 0 (0%) | |
| 3 | 0 (0%) | 0 (0%) | |
| Biological | 0 | 19 (35.2%) | 25 (46.3%) |
| 1 | 12 (22.2%) | 12 (22.2%) | |
| 2 | 23 (42.6%) | 17 (31.5%) |
Clinical involvement corresponding to each of the 12 domains is defined according to the ESSDAI. 0: no activity; 1: low activity; 2: moderate activity; 3: high disease activity. Sum of all frequencies do not add up to 55 in each group because of missing data. Percentages are computed on non-missing data.